{
    "clinical_study": {
        "@rank": "124413", 
        "arm_group": [
            {
                "arm_group_label": "Chemotherapy + T cells + IL-2", 
                "arm_group_type": "Experimental", 
                "description": "Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over15 minute period every 8-hours for up to 14 doses."
            }, 
            {
                "arm_group_label": "Chemotherapy + T cells + IL-2 + DCV", 
                "arm_group_type": "Experimental", 
                "description": "Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn if dendritic cell vaccine will increase the effect of\n      tumor infiltrating lymphocytes given with chemotherapy and interleukin-2 in patients with\n      melanoma."
        }, 
        "brief_title": "T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma", 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "The MAT02 clinical trial is a phase 1 clinical trial with the objective to assess the\n      safety, feasibility and immunological efficacy of the combined application of two\n      immunological treatment modalities in patients with metastatic melanoma:\n\n        1. Cohort A: After a non-myeloablative conditioning regimen, 5 patients will receive one\n           bulk infusion of T cells. T cells will be expanded ex vivo from autologous tumor\n           infiltrating lymphocytes (TIL). In vivo persistence of the infused cells will be\n           supported by administration of IL-2, a T cell survival factor.\n\n        2. Cohort B: This adoptive cell transfer (ACT) step will in additional 5 patients be\n           followed by a vaccination with autologous, in vitro-generated, dendritic cells (DC),\n           loaded with autologous tumor lysate and a synthetically produced peptide derived from\n           the tumor associated antigen NY-ESO 1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with measurable (direct on body surface or by x-ray and/or CT) malignant\n             cutaneous   melanoma, that is advanced, inoperable stage III (advanced regional lymph\n             node metastases, or more than 5 in-transit metastases, N2) or stage IV (distant\n             metastasis, M1) according to the AJCC classification and confirmed by\n             histology/cytology and appropriate radiological investigations.\n\n          -  Patients with a palpable resectable lesion located in the skin or in a lymph node or\n             a lesion accessible  by (core) biopsy. The lesion should be confirmed to be melanoma\n             by fine needle biopsy.\n\n          -  Disease should be in progression and the patient should have exhausted other approved\n             therapeutic options.\n\n          -  Ambulatory performance status (ECOG 0, 1, 2).\n\n          -  Age 18-74 and life expectancy greater than 3 months.\n\n          -  Patients must have been evaluated with imaging studies (MRI/CT/US/PET-CT) to\n             establish metastasis/advanced disease in the period of 30 days prior to the\n             initiation of the trial.\n\n        Exclusion Criteria:\n\n          -  Any of the above criteria are not met.\n\n          -  Significant history or current evidence of cardiovascular disease (e.g. uncontrolled\n             congestive heart failure or hypertension, unstable coronary artery disease or serious\n             arrhythmias) or major respiratory diseases. In questionable cases, a stress test\n             should be performed.\n\n          -  Recipients of a major organ allograft. Autoimmune diseases such as, but not limited\n             to, inflammatory bowel disease or multiple sclerosis. Vitiligo is not an exclusion\n             criterion. Other serious chronic diseases.\n\n          -  Other serious illnesses, e.g. active infections requiring antibiotics, bleeding\n             disorders.\n\n          -  Has had prior systemic cancer therapy within the past four weeks at the time of the\n             start of the lymphodepletion regimen.\n\n          -  Patients diagnosed with prior malignancies (except adequately treated basal cell\n             carcinomas of the skin or in situ carcinomas of the skin or in situ carcinomas of the\n             cervix, surgically cured).\n\n          -  Patients with second advanced malignancies concurrently.\n\n          -  CNS metastases. (Note: Patients with brain metastases that have been completely\n             resected at least one month prior to registration or have undergone gamma knife\n             treatment with no evidence of recurrence on CT and who are neurologically stable, are\n             not excluded).\n\n          -  Organic brain syndrome or significant psychiatric disorder which would preclude\n             participation in the full protocol and follow-up.\n\n          -  Immunodeficiency, previous splenectomy or radiation therapy of the spleen.\n\n          -  Screening laboratory values:\n\n             a) Inadequate hematologic function defined by: i) White blood count (WBC) <3.0 x\n             109/l ii)  Platelet count <100x109/l iii) Hemoglobin level <100 g/l b) Inadequate\n             hepatic function as defined by either: i) Total bilirubin level >1.5 times the upper\n             limit of normal (ULN) ii) Aspartate amino transferase (AST) or alanine amino\n             transferase (ALT) >3 times the ULN (if related to liver metastases >5 times the ULN)\n             c) Inadequate renal function defined as serum creatinine >1.5 times the ULN\n\n          -  Infectious diseases that can be transmitted via contact with blood, such as HIV,\n             Hepatitis B and C.\n\n          -  Women who are pregnant or nursing will be excluded because of the potentially\n             dangerous effects of the preparative chemotherapy on the fetus."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946373", 
            "org_study_id": "MAT-02", 
            "secondary_id": "2012-000450-63"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Chemotherapy + T cells + IL-2", 
                    "Chemotherapy + T cells + IL-2 + DCV"
                ], 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sendoxan", 
                    "Cytoxan", 
                    "Neosar"
                ]
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy + T cells + IL-2", 
                    "Chemotherapy + T cells + IL-2 + DCV"
                ], 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fludarabine phosphate", 
                    "Fludara"
                ]
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy + T cells + IL-2", 
                    "Chemotherapy + T cells + IL-2 + DCV"
                ], 
                "intervention_name": "T cells", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Chemotherapy + T cells + IL-2", 
                    "Chemotherapy + T cells + IL-2 + DCV"
                ], 
                "intervention_name": "Interleukin-2", 
                "intervention_type": "Biological", 
                "other_name": [
                    "IL-2", 
                    "Proleukin"
                ]
            }, 
            {
                "arm_group_label": "Chemotherapy + T cells + IL-2 + DCV", 
                "intervention_name": "Dendritic cell vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Fludarabine", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Melanoma", 
            "Dendritic cell vaccination", 
            "Lymphodepletion", 
            "Adoptive cell transfer", 
            "T cells", 
            "Tumor infiltrating lymphocytes", 
            "Fludarabine", 
            "IL-2", 
            "Interleukin-2", 
            "Cyclophosphamide", 
            "Phase I study", 
            "Monocytes", 
            "Autologous", 
            "NY-ESO-1"
        ], 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "contact": {
                "email": "roger.tell@karolinska.se", 
                "last_name": "Roger Tell, MD, PhD", 
                "phone": "+46760293911"
            }, 
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden", 
                    "zip": "SE-171 76"
                }, 
                "name": "Karolinska University Hospital"
            }, 
            "investigator": {
                "last_name": "Roger Tell, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma", 
        "overall_contact": {
            "email": "roger.tell@karolinska.se", 
            "last_name": "Roger Tell, MD, PhD", 
            "phone": "+46760293911"
        }, 
        "overall_contact_backup": {
            "email": "rolf.kiessling@ki.se", 
            "last_name": "Rolf Kiessling, MD, PhD", 
            "phone": "+46733428848"
        }, 
        "overall_official": {
            "affiliation": "Karolinska University Hospital", 
            "last_name": "Roger Tell, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety of the T cell therapy, with and without dendritic cell vaccine, as evaluated according to the NCI CTCAE scale version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946373"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska University Hospital", 
            "investigator_full_name": "Roger Tell", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Time to disease progression assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "source": "Karolinska University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}